Substantial changes foreseen in anti-hypertension drug markets.

Daewoong may introduce Olmetec, a new anti-hypertension drug, an angiotensin II receptor blocker, next year after its health registration completing in Oct. this year, which seems to cause a big change in the anti-hypertension drug markets.

Considering excellent therapeutic profiles of Olmetec with safety and tolerance compared to other drugs and powerful sales strength of Daewoong, a predi...